Abstract
A large number of patients in a group of Veterans Administration Hospitals received a variety of alkylating agents in studies in which these agents were randomized with an inert compound. Intravenous cyclophosphamide, and possibly nitrogen mustard, had a slight favorable influence upon survival for all patients. A difference between the two agents was seen: patients with squamous cell carcinoma appeared to respond best to nitrogen mustard therapy and patients with small cell undifferentiated carcinoma to cyclophosphamide therapy, in fairly striking fashion. Over-all influences upon survival, however, were not remarkable.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 516-525 |
| Number of pages | 10 |
| Journal | The American Journal of Medicine |
| Volume | 46 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1969 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Alkylating agents in bronchogenic carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS